PARSIPPANY, N.J.—In mid-October, Interpace Diagnostics Group Inc. presented new data at the 88th Annual Meeting of the American Thyroid Association (ATA) that support its molecular tests for thyroid cancer. The new interim data, spanning over 300 samples from a two-year “real world” retrospective study, highlighted the clinical utility of Interpace’s ThyGenX thyroid oncogene panel in combination with its micro-RNA classifier, ThyraMIR.
Nine centers from across the United States participated in this study, and the data reportedly demonstrated that ThyGenX/ThyraMIR combination test results help avoid unnecessary surgical resections and identify nodules where surgery is appropriate in cytologically indeterminate thyroid nodules. Importantly, the study also indicated that surgical decisions made based on the combination test results were appropriately aligned with risk of malignancy over clinical follow-up consistent with a combination test that effectively rules in and rules out higher risk of malignancy.
Recently, Interpace launched an expanded mutation panel called ThyGeNEXT, which includes additional markers such as TERT, PTEN, ALK and RET among others. As the company’s Clinical Experience Study progresses, patients tested with ThyGeNEXT will also be included to demonstrate the clinical utility of the latest version of the product.